# AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

> **NCT00372944** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 70 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** AZD6244
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00372944
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-04
- **Final completion:** 2008-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372944, "AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00372944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*